Get the Stockscreener App
0.9435
3.34%
-0.0326
Quince Therapeutics Inc stock is traded at $0.9435, with a volume of 320.87K.
It is down -3.34% in the last 24 hours and down -21.37% over the past month.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
See More
Previous Close:
$0.9761
Open:
$0.9468
24h Volume:
320.87K
Relative Volume:
0.07
Market Cap:
$18.45M
Revenue:
-
Net Income/Loss:
$-33.04M
P/E Ratio:
-0.1037
EPS:
-9.1023
Net Cash Flow:
$-39.66M
1W Performance:
-0.17%
1M Performance:
-21.37%
6M Performance:
-97.35%
1Y Performance:
-93.71%
1-Day Range:
$0.9281
$1.015
1-Week Range:
$0.90
$1.015
52-Week Range:
$0.79
$45.50
Quince Therapeutics Inc Stock (QNCX) Company Profile
Name
Quince Therapeutics Inc
Sector
Industry
Phone
415-910-5717
Address
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Compare QNCX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
0.9435 | 19.09M | 0 | -33.04M | -39.66M | -9.1023 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 121.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 65.01B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.26B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 39.14B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 37.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Aug-05-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-24-25 | Initiated | Oppenheimer | Outperform |
Quince Therapeutics Inc Stock (QNCX) Latest News
Quince Therapeutics, Inc. Files 8-K/A Amendment to Correct Reverse Stock Split Description – Key SEC Filing Details - Minichart
Quince Therapeutics (QNCX) confirms 1-for-20 reverse split and sharp share reduction - Stock Titan
1-for-20 reverse split consolidates Quince Therapeutics (NASDAQ: QNCX) shares - Stock Titan
Price to sales forward of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Enterprise value to revenue forward of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Price to book forward of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Quince Therapeutics, Inc. Actuals & Estimates (NASDAQ:QNCX) - TradingView
Cantor Fitzgerald reiterates Quince Therapeutics stock Overweight rating By Investing.com - Investing.com South Africa
QNCX Forecast — Price Target — Prediction for 2027 - TradingView
Cantor Fitzgerald reiterates Quince Therapeutics stock Overweight rating - Investing.com
Cantor Fitzgerald reiterates Quince Therapeutics stock rating at Overweight By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Quince Therapeutics stock rating at Overweight - Investing.com
QNCX Initiated Coverage by Leerink Partners -- Rating Set to Out - GuruFocus
Leerink Partners Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $4 - Moomoo
Leerink Partners Initiates Quince Therapeutics at Outperform With $4 Price Target - marketscreener.com
Leerink initiates Quince Therapeutics stock with Outperform rating - Investing.com
QNCX Initiated Coverage by Cantor Fitzgerald -- Rating Set to Ov - GuruFocus
Cantor Fitzgerald initiates Quince Therapeutics stock with overweight rating - Investing.com UK
Cantor Fitzgerald initiates Quince Therapeutics stock with overweight rating By Investing.com - Investing.com South Africa
Quince Therapeutics Inc. (QNCX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why Is QNCX Stock Up 60% Pre-Market After A Near-Total Wipeout? - Stocktwits
Cantor Fitzgerald Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $4 - Moomoo
Quince Therapeutics Inc (QNCX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Quince Therapeutics Stockbackground, strategy and long-term outlook - Ad-hoc-news.de
QUINCE THERAPEUTICS INC (QNCX) Stock Chart - ChartMill
Quince Therapeutics Inc (QNCX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Quince Therapeutics Inc (QNCX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Quince Therapeutics Inc (QNCX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Quince Therapeutics Inc (QNCX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Quince Therapeutics Inc (QNCX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Quince Therapeutics Inc (QNCX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Quince Therapeutics Inc (QNCX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Quince Therapeutics Inc (QNCX) Institutional Confidence - TradingKey
Quince Therapeutics (QNCX) director granted stock options for 2,700 shares - Stock Titan
Quince Therapeutics (QNCX) director receives 2,700 stock options grant - Stock Titan
Number of shareholders of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Quince Therapeutics (QNCX) Approves Reverse Stock Split—SEC 8-K Filing Details (June 11, 2026) - Minichart
Quince Therapeutics Stock (US74833Q1004): Stock in focus after shareholder analyst call - Ad-hoc-news.de
Quince Therapeutics (QNCX) officer awarded multi-million share option grants - Stock Titan
Quince Therapeutics (NASDAQ: QNCX) files Form 3 for officer Brigette Roberts - Stock Titan
Quince Therapeutics (NASDAQ: QNCX) wins approval for wide reverse split range - Stock Titan
Quince Therapeutics, Inc. announced that it has received $115.000298 million in funding from a group of investors - marketscreener.com
[SCHEDULE 13G] Quince Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
QNCX Q1 2026 Earnings: Unexpected Profit Driven by One-Time Items; Shares DipSurprise Factor Analysis - newsline.com
Quince Therapeutics Inc. (QNCX) Q1 2026 Earnings: Massive EPS Surprise Driven by Non-Operating Items, Stock DeclinesNet Profit Margin - newsline.com
Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy - Insider Monkey
5 Popular Penny Stocks on Robinhood to Watch in 2026 - Insider Monkey
Quince Therapeutics stock (US74833Q1004): Nasdaq-listed biotech rebounds after regaining compliance - AD HOC NEWS
Why is QNCX stock up 60% pre-market after a near-total wipeout? - MSN
Quince Therapeutics (QNCX) Edges Higher: Navigating Key Levels Near ResistanceCovered Call ETF - newsline.com
Quince Therapeutics Inc. (QNCX) Q1 2026 Earnings: Surprise Profitability as EPS Beats Estimates by Over 200% - thelegaladvocate.com
Quince Therapeutics Inc Stock (QNCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):